Pcv152 - Treatment Burden Associated With Different Anticoagulation Strategies of Atrial Fibrillation Patients: An Observational Study in Germany, Sweden and Switzerland Based on the Anti-Clot Treatment Scale

Wilke, Thomas; Bloempott, S.; Henry, Maren; Mueller, Sebastian

doi:10.1016/j.jval.2018.09.697

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some did not demonstrate or report that dissatisfaction from previous NOAC or VKA treatment was not present at the start. 14,33,[44][45][46][47] Additionally, in some studies the outcome was assessed by nonblinded interviewers. 40,41,43,48,49 Moreover, in three studies there may be bias regarding the patients lost to follow-up.…”

Section: Risk Of Biasmentioning

confidence: 99%

See 1 more Smart Citation

Satisfaction of Patients with Nonvitamin K Anticoagulants Compared to Vitamin K Antagonists: a Systematic Review and Meta-analysis

et al. 2020

View full text Add to dashboard Cite

Objective To undertake a systematic review and meta-analysis to assess the satisfaction of patients receiving nonvitamin K anticoagulants (NOACs), compared with vitamin K antagonists (VKAs). Methods We searched CENTRAL, MEDLINE, Embase, and Clinicaltrials.gov for randomized controlled trials (RCTs) and observational studies. Two reviewers screened, extracted, and appraised data independently. We pooled data using a random-effects model. Outcome included treatment satisfaction, which was assessed by scores of Duke Anticoagulation Satisfaction Scale (DASS), Anticlot Treatment Scale (ACTS), Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2), or Treatment Satisfaction Questionnaire for Medication version II (TSQM-VII) and their domains reported with 95% confidence intervals (95% CIs). We followed MOOSE and PRISMA guidelines. Results We included four RCTs and 16 observational studies, enrolling 18,684 participants overall. Compared with VKAs, treatment with NOACs improved the ACTS Burdens score by 4.21 points (95% CI: 2.99–5.43, I 2 = 95%, combined n = 6,180), and ACTS Benefits by 0.49 points (95% CI: 0.18–0.81, I 2 = 85%, combined n = 6,171). Switching from VKAs to NOACs improved the ACTS Burdens score by 5.33 points (95% CI: 3.53–7.14, combined n = 3,097). Compared with VKAs, treatment with NOACs improved the TSQM-VII Global Satisfaction score by 6.86 points (95% CI: 3.00–10.73, combined n = 5,535). Conclusion In patients with nonvalvular atrial fibrillation or venous thromboembolism, NOAC treatment is associated with greater satisfaction compared with VKAs. The switch from VKAs to NOACs was associated with improved patients' satisfaction. These effects were largely due to a lower degree of treatment burden with NOAC treatment.

show abstract

Section: Risk Of Biasmentioning

confidence: 99%

“…14 The results from Wilke et al showed a higher treatment burden in the VKA group, in comparison with NOAC treatment, and no statistical differences between perceived benefits. 47…”

Section: Dass Scalementioning

confidence: 99%